# Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

> **NCT03417544** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nancy Lin, MD** · enrollment: 19 (actual)

## Conditions studied

- HER2-positive Metastatic Breast Cancer
- Central Nervous System Metastases

## Interventions

- **DRUG:** ATEZOLIZUMAB
- **DRUG:** PERTUZUMAB
- **DRUG:** TRASTUZUMAB

## Key facts

- **NCT ID:** NCT03417544
- **Lead sponsor:** Nancy Lin, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-21
- **Primary completion:** 2020-05-20
- **Final completion:** 2026-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417544, "Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03417544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*